Today: 21 May 2026
Google stock price: GOOG faces antitrust pause bid — what to watch before Tuesday’s open
18 January 2026
2 mins read

Google stock price: GOOG faces antitrust pause bid — what to watch before Tuesday’s open

New York, January 18, 2026, 09:43 EST — Market closed

  • Alphabet Class C (GOOG) slipped 0.8% to close Friday at $330.34
  • Google is pushing to halt certain search antitrust measures as it moves forward with its appeal
  • Upcoming highlights: Jan. 22 PCE inflation figures and Alphabet’s earnings call on Feb. 4

Alphabet Inc’s Class C shares (GOOG.O) slipped 0.8% to close at $330.34 on Friday, after moving between $329.03 and $333.69 during the session. The company asked a U.S. judge to halt a court-ordered fix that would compel it to share search data with competitors while it challenges a ruling that deemed its online search monopoly illegal. Google told the court it’s “prepared to do everything short of turning over its data” as the appeal proceeds, even as U.S. regulators consider tougher measures, including a possible Chrome divestiture and ending default-search payments. Reuters

The filing arrives while Alphabet shares hover near recent peaks, following a sharp rally earlier this month that briefly pushed the company’s valuation to $4 trillion. At that time, Alphabet announced Apple’s upcoming AI models would rely on Google’s Gemini under a multi-year agreement—a key detail that boosted enthusiasm for its AI strategy.

This matters now because the remedies battle hits the core of what keeps Google Search dominant: distribution deals that set Google as the default on new devices, and access to data that rivals need to develop competitive products.

Google’s request arrives during a holiday-shortened stretch, with U.S. markets closed Monday and not reopening until Tuesday. That gap often complicates single-stock trades; legal developments and a quiet Monday news flow carry extra weight.

Google’s vice president of regulatory affairs, Lee-Anne Mulholland, pushed back in a blog post against the August 2024 ruling, saying it “ignored the reality that people use Google because they want to, not because they’re forced to.” She warned that mandating Google to share search data and offer “syndication services” — allowing others to display its search results and ads — would “risk Americans’ privacy” and weaken incentives for competitors to develop their own products. blog.google

Google’s legal troubles go beyond the antitrust battle. On Friday, a U.S. appeals court dismissed the Republican National Committee’s bid to bring back a lawsuit. The suit accused Google of routing the party’s fundraising emails into Gmail users’ spam folders. This case has kept the company caught up in politically charged disputes over how its products manage and display content.

Friday’s action was muted across the board. U.S. stocks closed almost unchanged ahead of the long weekend. Ameriprise chief market strategist Anthony Saglimbene noted that “most investors will take that as a win” following a volatile start to the year. Reuters

Thursday puts GOOG traders on alert with the release of the Personal Consumption Expenditures Price Index (PCE) on Jan. 22, the Fed’s go-to inflation measure. Bond yields and rate expectations often shape the valuation of mega-cap growth stocks like Google.

Alphabet is gearing up for its next big event. The company will hold its fourth-quarter and full-year 2025 earnings call on Feb. 4 at 4:30 p.m. Eastern, following the earnings release earlier that day.

The downside is clear, though the timing remains uncertain. The judge might deny the pause on data-sharing and syndication rules. On top of that, the Justice Department and states could push for tougher measures on appeal — a move that would increase the chances of major shifts in distribution agreements and Search’s business model.

Investors will be eyeing Tuesday’s open to see if legal troubles begin to overshadow the AI-fueled rally that’s pushed shares up. The key dates ahead are Jan. 22 for PCE data, Feb. 3 when regulators decide on appealing for tougher penalties, and Feb. 4, which brings Alphabet’s earnings and guidance.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Intuitive Machines stock jumped 11% Friday — here’s what matters before the next trade
Previous Story

Intuitive Machines stock jumped 11% Friday — here’s what matters before the next trade

JPMorgan stock heads into Tuesday with Trump lawsuit threat and credit-card cap in focus
Next Story

JPMorgan stock heads into Tuesday with Trump lawsuit threat and credit-card cap in focus

Go toTop